GCN2-IN-1 (C007B-357618)

Catalog No.: C007B-357618
Manufacturer No.: G649297-5mg
Manufacturer Name: Aladdin Scientific
Quantity: 1
Unit of Measure: EA

GCN2-IN-1 (A-92) is a potent general control nonderepressible 2 kinase ( GCN2 ) inhibitor with an IC 50 of <:0.3 μM in the enzyme assay and an IC 50 of 0.3-3 μM in the cell assayIn VitroGCN2-IN-1 (Compound A-92) is a GCN2 inhibitor, which may be

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Description
Specifications

GCN2-IN-1 (A-92) is a potent general control nonderepressible 2 kinase ( GCN2 ) inhibitor with an IC 50 of <0.3 μM in the enzyme assay and an IC 50 of 0.3-3 μM in the cell assayIn VitroGCN2-IN-1 (Compound A-92) is a GCN2 inhibitor, which may be useful as a chemotherapeutic drug for the treatment of cancer. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:eIF2.

Specifications and Purity: ≥98%

Molecular Formula: C19H18N10O

Molecular Weight: 402.41

PubChem CID: 89720372

Isomeric SMILES: C1COCCC1N2C=C(C=N2)NC3=NC=C4C(=N3)N(N=N4)C5=CC6=C(C=C5)C=NN6

UPC:: 12141728
Condition:: New
HazmatClass:: No
WeightUOM:: LB
MPN:: G649297-5mg
CAS:: 1448693-69-3
Product Size:: 5mg

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."